lobster
发表于 2025-3-26 23:28:36
Dave Cowan,Helen Carr,Alison Wallace the only therapy that has proven to be curative for hematological malignancies. The search for a more specific and, hopefully, less toxic therapeutic approach using immune system cells that are redirected toward the target of interest is needed and ongoing. This could be potentially accomplished by
套索
发表于 2025-3-27 01:47:13
http://reply.papertrans.cn/23/2230/222902/222902_32.png
多嘴多舌
发表于 2025-3-27 05:33:49
Cell and Gene Therapies978-3-319-54368-0Series ISSN 2569-1376 Series E-ISSN 2569-135X
有其法作用
发表于 2025-3-27 12:24:14
http://reply.papertrans.cn/23/2230/222902/222902_34.png
Irksome
发表于 2025-3-27 16:30:52
Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018,ogenic disorders (Gardner et al., Blood 129:3322–3331, 2017) (refer to subsequent disease-specific chapters in the book). In this chapter, we will highlight the most recent and clinically relevant developments in the arena of gene-modified T-cell-based therapies and hematopoietic stem cellular gene
Geyser
发表于 2025-3-27 18:50:43
Chimeric Antigen Receptor T Cells for Leukemias in Children: Methods, Data, and Challengesgation for treatment of relapsed ALL. Whole-genome sequencing has allowed characterization of the transcriptional profile of the leukemic cell, facilitating targeted therapy and leading us one step closer to precision medicine. In this rapidly evolving “race” for better and nontoxic treatments, we f
赔偿
发表于 2025-3-27 22:04:29
http://reply.papertrans.cn/23/2230/222902/222902_37.png
圆柱
发表于 2025-3-28 03:14:01
Cytotoxic T Cells for Infections: From Donor Specific to “Off the Shelf”the deficiencies in viral immunity post-transplant. In this review, we begin by detailing the advances made in producing single-virus-specific T cells, in particular for CMV and EBV, and then proceed to describe the progress in developing multi-virus-specific T cells and in broadening the repertoire
Ligneous
发表于 2025-3-28 09:48:06
Regulatory T Cells: Broadening Applicability even prevent this fatal complication in the clinical setting. Ultimately, researchers and clinicians want to find a way to establish long-lasting tolerance within the graft without diminishing the beneficial graft-versus-tumor/graft-versus-leukemia (GvT/GvL) effect..The chapter will give an overvie
Graduated
发表于 2025-3-28 11:38:39
http://reply.papertrans.cn/23/2230/222902/222902_40.png